Shots:

• GSK to receive shares of Fulcrum's preferred stock- milestones & royalties on sales of losmapimod. Fulcrum to get exclusive WW rights to develop & commercialize of losmapimod with all patent rights
• Fulcrum has conducted pre-clinical testing of losmapimod and identified it as potent regulator of DUX4 gene. In mid-2019- Fulcrum plans for the onset of P-IIb trial of losmapimod in patients with FSHD across multiple sites in the US and Europe
• Losmapimod is a selective p38α/β mitogen activated protein kinase (MAPK) inhibitor- evaluated in 3-500 candidates for multiple indication in 24 clinical studies

Ref: Fulcrum Therapeutics | Image: GSK